RVNC (Revance Therapeutics) חוב לטווח קצר להון

Due to grueling dumping in the aesthetics niche, Revance Therapeutics (RVNC) was forced to merge with another player to preserve its brand. Fierce competition with industry behemoths possessing colossal advertising budgets created serious risks. The company is currently developing a closed B2B environment around Daxxify to retain clinics within its network. The asset value of 0.00 shown on this chart reflects the current financial state of this business.

This indicator assesses financial stability through the ratio of liabilities maturing within one year to equity, where the short-term debt-to-equity ratio visualizes the company's reliance on operational borrowing. For the biopharmaceutical business of Revance Therapeutics (RVNC), which operates under strict FDA regulations, such a financing structure is critical to ensuring the current utilization of biomaterials without risking a loss of solvency.